RNA-seq analysis of MDA-MB-231 triple-negative breast cancer cells treated with CIr2 for 24 h
This study investigates the transcriptomic alterations induced by a novel cyclometalated iridium(III) compound, CIr2, in triple-negative breast cancer (TNBC) cells. MDA-MB-231 cells were treated with CIr2 for 24 h, followed by RNA sequencing to profile global gene expression changes. The RNA-seq data were integrated with functional assays and morphological analyses to explore cellular responses associated with mitochondrial dysfunction, reactive oxygen species production, endoplasmic reticulum stress, and MAPK signaling. This dataset provides a resource for examining CIr2-induced transcriptional programs related to non-apoptotic cell death pathways in TNBC cells. Overall design: RNA-seq was performed to compare global gene expression profiles of MDA-MB-231 triple-negative breast cancer cells treated with vehicle control or 500 nM CIr2 for 24 h.